Company Overview and News

15
Cobalt Miners News For The Month Of August 2018

2018-08-23 seekingalpha
Cobalt miner news - BHP seeking to add cobalt sulphate from Nickel West operation. China Molybdenum net profit set to surge between 271.21% and 295.16%.
SIE PIO CLA PANRF BLT CCZ PAN HAV MCR KBGCF CTM AXE ECSIF IGO VIC BAR AOU HIG PCRCF PLM.RT SNNAF FQM MCRZF BXTMF MLX PSDNF POM AYR CDU RGARF CHK MCRZY FTMDF KAT RER BBL CSSQF BHPLF GMRSF CZN PGM GBLEF NZRIF AZS GLCNF DLE HBNRF MEI PIONF GAL CZI AMSLF BPLNF HMI POS AUZ RNX GME FQVLF AQR PTNUF FT BHPBF HNLMF ORR CDNMD 3993 UMICY CDNMF IIDDY AEOMF USCFF FTSSF KATFF BBBMF MLXEF OZMLF PLM BHP CNJ AZRMF HLPCF BPL BHP OZL ARV

17
Cobalt Miners News For The Month Of July 2018

2018-07-23 seekingalpha
Cobalt market news - Darton forecasts 40% growth in cobalt demand in 2018. Tony Southgate (ERG) says: "The cobalt boom is guaranteed for the next seven to 10 years."
SIE PIO CLA PANRF RIO CCZ PAN HAV MCR KBGCF CTM FCX AXE IGO VIC BAR AOU HIG PCRCF PLM.RT SNNAF FQM MCRZF BXTMF MLX PSDNF POM AYR SHERF CDU RGARF CHK MCRZY CLQ FTMDF KAT RIO RER CSSQF GMRSF CZN PGM GBLEF NZRIF RIO AZS GLCNF DLE HBNRF MEI PIONF CZI AMSLF BPLNF HMI POS AUZ RNX RTPPF GME RTNTF FQVLF AQR PTNUF FT HNLMF ORR CDNMD 3993 UMICY CDNMF IIDDY AEOMF USCFF FTSSF KATFF BBBMF MLXEF OZMLF PLM CNJ AZRMF HLPCF BPL BHP OZL ARV

208
Cobalt Miners News For The Month Of March 2018

2018-03-25 seekingalpha - 1
Cobalt spot price news - Spot prices rise 18.7% in the past month as inventory falls. The cobalt spot price is now over USD 40/lb, and approaching USD 100,000/tonne.
SIE PIO PANRF HAV PAN KBGCF MCR FCX ECSIF IGO VIC BAR AOU HIG PLM.RT TAKRF UMICF SNNAF FQM LGI MCRZF BXTMF MLX PSDNF POM CDU RGARF CHK VLKAF MCRZY FTMDF KAT RER CSSQF GMRSF CZN PGM GBLEF NZRIF AZS GLCNF DLE HBNRF MEI PIONF CZI AMSLF HMI POS AUZ RNX GME AAPL FQVLF AQR MBL PTNUF FT HNLMF ORR CDNMD 3993 UMICY CDNMF IIDDY AEOMF USCFF KATFF MLXEF OZMLF PLM S CNJ AZRMF HLPCF BHP OZL ARV

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...